Page 2,663«..1020..2,6622,6632,6642,665..2,6702,680..»

PropThink: STEM Gains on Anticipation of Interim Trial Data to be Presented Monday

Posted: August 31, 2012 at 11:14 pm

Stem Cells Inc, (STEM), developer of stem cell-based treatments for spinal injury, is up for the second day in a row Friday in pre-market trading, after it closed Thursday at $1.96, a 19% gain on the day. The gains came after the company announced that it will be presenting data from its Phase I/II clinical trial on Monday, Sept. 3 at the International Spinal Cord Society and will hold a conference call the following day. Trading volume Thursday was three times its 3-month average. The presentation will include interim data from the study`s first cohort, which has three partially paralyzed patients being treated with STEM`s proprietary HuCNS-SC cells. Researchers are looking for efficacy - measured by improvement in motor function, sensation, and bladder control - and safety in the first of three planned cohorts, each with more mild paralysis than the previous. Share price is likely to remain strong on Friday and into the meeting, as most analysts expect some positive results from the trial. If Monday`s data looks good for STEM, shares may climb higher on momentum, however, negative results will have disastrous effects on the stock. STEM is up 140% in 2012.

Click here to see this article at PropThink.com.

About PropThink

PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com. To learn more visit us at http://www.propthink.com.

The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: PropThink via Thomson Reuters ONE HUG#1637958

Go here to read the rest:
PropThink: STEM Gains on Anticipation of Interim Trial Data to be Presented Monday

Posted in Stem Cell Videos | Comments Off on PropThink: STEM Gains on Anticipation of Interim Trial Data to be Presented Monday

UCLA Researchers Discover "Missing Link" Between Stem Cells and the Immune System

Posted: August 31, 2012 at 11:14 pm

Newswise UCLA researchers have discovered a type of cell that is the missing link between bone marrow stem cells and all the cells of the human immune system, a finding that will lead to a greater understanding of how a healthy immune system is produced and how disease can lead to poor immune function.

The studies were done using human bone marrow, which contains all the stem cells that produce blood during postnatal life.

We felt it was especially important to do these studies using human bone marrow as most research into the development of the immune system has used mouse bone marrow, said study senior author Dr. Gay Crooks, co-director of the Eli and Edythe Broad Center of Regenerative Medicine and a co-director of the Cancer and Stem Cell Biology program at UCLAs Jonsson Comprehensive Cancer Center. The few studies with human tissue have mostly used umbilical cord blood, which does not reflect the immune system of postnatal life.

The research team was intrigued to find this particular bone marrow cell because it opens up a lot of new possibilities in terms of understanding how human immunity is produced from stem cells throughout life, said Crooks, a professor of pathology and pediatrics.

Understanding the process of normal blood formation in human adults is a crucial step in shedding light on what goes wrong during the process that results in leukemias, or cancers of the blood.

The study appears Sept. 2 in the early online edition of Nature Immunology.

Before this study, researchers had a fairly good idea of how to find and study the blood stem cells of the bone marrow. The stem cells live forever, reproduce themselves and give rise to all the cells of the blood. In the process, the stem cells divide and produce intermediate stages of development called progenitors, which make various blood lineages like red blood cells or platelets. Crooks was most interested in the creation of the progenitors that form the entire immune system, which consists of many different cells called lymphocytes, each with a specialized function to fight infection.

Like the stem cells, the progenitor cells are also very rare, so before we can study them we needed to find the needle in the haystack. said Lisa Kohn, a member of the UCLA Medical Scientist Training Program and first author in the paper.

Previous work had found a fairly mature type of lymphocyte progenitor with a limited ability to differentiate, but the new work describes a more primitive type of progenitor primed to produce the entire immune system, Kohn said

Once the lymphoid primed progenitor had been identified, Crooks and her team studied how gene expression changed during the earliest stages of its production from stem cells.

Follow this link:
UCLA Researchers Discover "Missing Link" Between Stem Cells and the Immune System

Posted in Stem Cell Videos | Comments Off on UCLA Researchers Discover "Missing Link" Between Stem Cells and the Immune System

Press Release

Posted: August 31, 2012 at 9:10 pm

Research and MarketsPosted on:31 Aug 12

Research and Markets (http://www.researchandmarkets.com/research/9fkkzb/cell_therapy_tec) has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering.

This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

The cell-based markets was analyzed for 2011, and projected to 2021. The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 284 of these are profiled in part II of the report along with tabulation of 274 alliances. Of these companies, 154 are involved in stem cells. Profiles of 70 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 55 Tables and 11 Figures. The bibliography contains 1,050 selected references, which are cited in the text.

Key Topics Covered:

Continue reading here:
Press Release

Posted in Cell Therapy | Comments Off on Press Release

Research and Markets: Cell Therapy – Technologies, Markets and Companies – Updated 2012 Report

Posted: August 31, 2012 at 9:10 pm

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/9fkkzb/cell_therapy_tec) has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering.

This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

The cell-based markets was analyzed for 2011, and projected to 2021. The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 284 of these are profiled in part II of the report along with tabulation of 274 alliances. Of these companies, 154 are involved in stem cells. Profiles of 70 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 55 Tables and 11 Figures. The bibliography contains 1,050 selected references, which are cited in the text.

Key Topics Covered:

See the article here:
Research and Markets: Cell Therapy - Technologies, Markets and Companies - Updated 2012 Report

Posted in Cell Therapy | Comments Off on Research and Markets: Cell Therapy – Technologies, Markets and Companies – Updated 2012 Report

‘Flip-flop’ switch discovered behind key cellular process

Posted: August 31, 2012 at 7:16 pm

The molecular circuitry controlling asymmetric cell division in roots resembles a flip-flop switch.

(Phys.org)For organisms to grow and develop, they must produce tissues with distinct functions, each one made up of similar cells. These different tissues are derived from stem cells. How stem cells divide to create new cell types is known as asymmetric cell division, and is obviously crucial to the overall development of the organism. In plants, whose cells cannot migrate, the location where a stem cell undergoes asymmetric cell division must also be crucial to ensuring tissues develop in the correct place.

In research published in the journal Cell, a collaboration between theoretical biologists and experimentalists, headed by Stan Mare of the John Innes Centre, and Ben Scheres, of the University of Utrecht, the Netherlands, uncovered a molecular switch that integrates signals to ensure these asymmetric cell divisions happen in the right place and at the right time, to produce layers of specialised tissue in the root.

"Through an experimental-modelling cycle, we have unravelled how stem cells in the Arabidopsis root regulate asymmetric cell divisions that give rise to two new cell identities at the correct position," said Dr Stan Mare of the John Innes Centre, which is strategically funded by the Biotechnology and Biological Sciences Research Council. "We dissected the underlying molecular circuit which operates in each cell, and found that it presented a highly robust bistable behaviour, due to two positive feedback loops involving the proteins SHR, SCR and the cell-cycle related players RBR and CYCLD6;1. In other words, we showed that the circuit behaves like a switch."

Bistable systems, which can only exist in one of two states, are found in nature where tight control is needed. Positive feedback loops are common features of them as they help make the rapid switch from one state to another.

Having identified this switch, the next step was to work out how the plant turns it on and off, so that only the correct stem cells perform asymmetric division, and in the right location for the overall development of the plant.

To do this, Dr Stan Mare together with Dr Vernica Grieneisen constructed a mathematical model, an in silico version of the root and the molecular circuitry behind the switch.

The physical location of an asymmetric cell division relies on the interaction of the plant hormone auxin and the protein SHR. Previous work by Dr Grieneisen had shown how auxin accumulates in the root tip through a reflux-loop mechanism established by polarly localized auxin efflux carriers in cells, and that the concentration of auxin declines the further from the root tip, forming a gradient with its highest peak at the stem cells.SHR protein sets up a similar gradient, but perpendicular to the auxin gradient, radiating out.

"We found that the cells that undergo these special cell divisions are located right at the crossroads of these two gradients," said Dr Grieneisen.

The cell divisions also trigger protein degradation, which turns the switch off again. This is needed to prevent uncontrolled development.

Read more:
'Flip-flop' switch discovered behind key cellular process

Posted in Stem Cells | Comments Off on ‘Flip-flop’ switch discovered behind key cellular process

PropThink: STEM Gains on Anticipation of Interim Trial Data to be Presented Monday

Posted: August 31, 2012 at 7:16 pm

Stem Cells Inc, (STEM), developer of stem cell-based treatments for spinal injury, is up for the second day in a row Friday in pre-market trading, after it closed Thursday at $1.96, a 19% gain on the day. The gains came after the company announced that it will be presenting data from its Phase I/II clinical trial on Monday, Sept. 3 at the International Spinal Cord Society and will hold a conference call the following day. Trading volume Thursday was three times its 3-month average. The presentation will include interim data from the study`s first cohort, which has three partially paralyzed patients being treated with STEM`s proprietary HuCNS-SC cells. Researchers are looking for efficacy - measured by improvement in motor function, sensation, and bladder control - and safety in the first of three planned cohorts, each with more mild paralysis than the previous. Share price is likely to remain strong on Friday and into the meeting, as most analysts expect some positive results from the trial. If Monday`s data looks good for STEM, shares may climb higher on momentum, however, negative results will have disastrous effects on the stock. STEM is up 140% in 2012.

Click here to see this article at PropThink.com.

About PropThink

PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com. To learn more visit us at http://www.propthink.com.

The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: PropThink via Thomson Reuters ONE HUG#1637958

View original post here:
PropThink: STEM Gains on Anticipation of Interim Trial Data to be Presented Monday

Posted in Stem Cells | Comments Off on PropThink: STEM Gains on Anticipation of Interim Trial Data to be Presented Monday

Press Release

Posted: August 31, 2012 at 7:15 pm

Research and MarketsPosted on:31 Aug 12

Research and Markets (http://www.researchandmarkets.com/research/9fkkzb/cell_therapy_tec) has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering.

This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

The cell-based markets was analyzed for 2011, and projected to 2021. The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 284 of these are profiled in part II of the report along with tabulation of 274 alliances. Of these companies, 154 are involved in stem cells. Profiles of 70 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 55 Tables and 11 Figures. The bibliography contains 1,050 selected references, which are cited in the text.

Key Topics Covered:

Visit link:
Press Release

Posted in Cell Therapy | Comments Off on Press Release

Research and Markets: Cell Therapy – Technologies, Markets and Companies – Updated 2012 Report

Posted: August 31, 2012 at 7:15 pm

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/9fkkzb/cell_therapy_tec) has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering.

This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

The cell-based markets was analyzed for 2011, and projected to 2021. The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 284 of these are profiled in part II of the report along with tabulation of 274 alliances. Of these companies, 154 are involved in stem cells. Profiles of 70 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 55 Tables and 11 Figures. The bibliography contains 1,050 selected references, which are cited in the text.

Key Topics Covered:

Read more:
Research and Markets: Cell Therapy - Technologies, Markets and Companies - Updated 2012 Report

Posted in Cell Therapy | Comments Off on Research and Markets: Cell Therapy – Technologies, Markets and Companies – Updated 2012 Report

Stem Cells Bring New Hope for Parry-Romberg Syndrome Patients

Posted: August 31, 2012 at 11:17 am

SEOUL, South Korea, Aug. 31, 2012 /PRNewswire/ -- In a landmark clinical study, scientists of the RNL Stem Cell Technology Institute have demonstrated that the transplant of patients' own ("autologous") stem cells can dramatically improve the ability of plastic surgeons to repair diseases. In the September 2012 issue of the prestigious international plastic surgery journal Annals of Plastic Surgery (69:3), researchers published their controlled study of the power of stem cells, describing a breakthrough with patients who have Parry-Romberg Syndrome. More than 200,000 have this tragic and debilitating disease in the U.S. alone. Their prognosis without treatment is the slow loss of control, then paralysis of the face and in some cases the mouth and even eyes. Most patients with Parry-Romberg begin to experience these symptoms between the age of five (5) and fifteen (15) years of age. There is, says the National Institute of Neurological Disorders and Stroke of the U.S. National Institutes of Health, "no cure." To date, treatments have involved waiting until the disease slows and then transplanting fat into patients' faces, strengthening bones in their faces, and using microvascular surgery to "install" a free flap of skin.

However the only solution for patients with this disorder, and those with similar disorders, the grafting of fat, is at best a temporary solution, which alleviates none of the pain felt by these patients, and can in fact result in an increase in pain when fat grafts fail. So, plastic surgeons, engineers and others have searched for years for a solution with longer term effects, or even a way to fight the disease's symptoms in a sustained way.

Dr. Kyeung-Suk Ko and Dr. Jong-Woo Choi led a research team under Dr. Jeong-chan Ra of RNL Stem Cell Technology Institute that may have uncovered, for the first time, just such a tool for plastic surgeons: patients' own stem cells. In their controlled study, the team painlessly removed a few ounces of fat from one group Parry-Romberg Syndrome patients, harvesting stem cells from these patients' fat, cells that are genetically identical to the patient's cells throughout their body and that have well documented abilities to "home in" on inflammation and disease and have dramatic effects on patients' symptoms and even disease itself. In this study, those patients in the "treated" group received stem cells magnified into the millions (using the team's patented technology whose safety has been well published). These patients' outcomes, adding stem cells to standard-of-care therapies, were measured against traditional microfat grafts in the control group receiving no stem cells.

In what many have described as a revolutionary finding, the team found that those patients who received their own "adult" mesenchymal stem cells saw unprecedented improvement in the effectiveness of therapies. Fat grafts that are often "resorbed" into patients' skin shortly after they are placed were 50% less likely to disappear when provided alongside stem cells (20.59% vs 46.81%).

This study was approved by the Korea Food and Drug Administration, the institutional IRB of the Asan Medical Center, and peer-reviewed prior to acceptance in the renowned plastic surgery publication under the title: "Clinical application of human adipose tissue-derived mesenchymal stem cells in progressive hemifacial atrophy (Parry-Romberg Disease) with microfat grafting techniques using three-dimensional computed tomography and three-dimensional camera." Authors and investigators included: Koh KS, Oh TS, Kim H, Chung IW, Lee KW, Lee HB, Park EJ, Chung JS, Shin IS, Ra JC, Choi JW. Media and others may access the article at http://journals.lww.com/annalsplasticsurgery/Abstract/2012/09000/Clinical_Application_of_Human_Adipose.22.aspx. Its National Library of Medicine ID is PMID:22878516.

Dr. Ra, senior author, said, "We believe that this is a big step for Parry-Romberg Syndrome patients and expect to see autologous stem cell transplantation as standard of care for their treatment. The next step is to test the efficacy of the many ways in which stem cells from adults' own bodies will expand the quality of life and even identify cures for many rare diseases."

View original post here:
Stem Cells Bring New Hope for Parry-Romberg Syndrome Patients

Posted in Stem Cell Videos | Comments Off on Stem Cells Bring New Hope for Parry-Romberg Syndrome Patients

Verastem to Present at Upcoming Investor Conferences

Posted: August 31, 2012 at 2:11 am

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Verastem, Inc., (VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced presentations at several upcoming investment conferences. The presentation details are as follows:

A webcast of each presentation can be accessed by visiting the investors section of the Companys website at http://www.verastem.com. A replay of the webcast will be archived on the Verastem website for two weeks following the presentation date.

About Verastem, Inc.

Verastem, Inc. (VSTM) is a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. For more information please visit http://www.verastem.com.

Forward-looking statements:

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements.Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Companys views to change.However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

More:
Verastem to Present at Upcoming Investor Conferences

Posted in Stem Cell Videos | Comments Off on Verastem to Present at Upcoming Investor Conferences

Page 2,663«..1020..2,6622,6632,6642,665..2,6702,680..»